Hyloris Pharmaceuticals (FRA:52U) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:52U Hyloris Pharmaceuticals SA FRA:52U
69 GF Score
Price €4.15
GF Value €8.59
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals 3-Month Share Buyback Ratio?

Hyloris Pharmaceuticals FRA:52U -0.95% 69 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates FRA:52U with a GF Score™ of 69/100 and a GF Value™ of €8.59 (Possible Value Trap). The stock has 3 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:52U
69GF Score
Hyloris Pharmaceuticals SA FRA:52U
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Hyloris Pharmaceuticals (FRA:52U) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' 3-Month Share Buyback Ratio too high?
Hyloris Pharmaceuticals' current 3-Month Share Buyback Ratio is 0.00. Overall, Hyloris Pharmaceuticals has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' 3-Month Share Buyback Ratio compare to VRTX and REGN?
Hyloris Pharmaceuticals' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (FRA:52U) is currently considered Possible Value Trap. The stock's GF Value™ is €8.59, compared to a current price of €4.15 — trading 51.7% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Hyloris Pharmaceuticals' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Hyloris Pharmaceuticals (FRA:52U), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (FRA:52U) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.15 is trading 51.7% below its estimated GF Value™ of €8.59. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:52U:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €8.59 vs. price of €4.15 (51.7% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:52U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 0AB6:UKHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
69GF Score

Get the complete analysis for FRA:52U

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.15
Price
€8.59
GF Value